Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 24 December 2025 - 6 January 2026

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC The case matters for Travere because FSGS is a rare disease that scars the kidney’s filtering units and can progress to kidney failure. An added label would broaden
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

New York, January 5, 2026, 14:35 ET — Regular session Johnson & Johnson (JNJ) stock fell about 2.2% on Monday as investors trimmed defensive healthcare names. Shares were down $4.49 at $202.86 in afternoon trading after touching a session low of $200.94, with about 4.8 million shares traded. The timing matters because early-year positioning has shifted quickly toward cyclicals, leaving traditionally steady names with less of a bid. When money flows out of defensives, big healthcare stocks can slide even without a single headline. Investors are also recalibrating around legal and earnings catalysts that can reprice a stock in a
5 January 2026
···
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares. Businessinsider Why it matters now: priority review shortens the FDA’s review target to six months, versus 10 months under the standard process, pulling a key binary catalyst into the first
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive The selloff matters because relacorilant was the company’s key near-term bet to broaden its commercial base beyond its current product, and the FDA’s response forces investors to reassess both timing and risk. It also sharpens focus on Corcept’s oncology program. In the
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters The decision hits at a key moment for Corcept, which investors have looked to relacorilant to expand the company’s business beyond its marketed drug Korlym. A regulatory setback for relacorilant raises the risk that Corcept’s next growth driver takes longer—and costs more—to reach the market. Reuters Corcept
1 January 2026
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover chatter earlier this month. Reuters reported on Dec. 10 that Abivax jumped on market rumours that Eli Lilly could make an offer, and Stifel analyst Damien Choplain said the “share price movement is driven by speculation around a possible takeover.”
31 December 2025
··
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

NEW YORK, December 30, 2025, 23:30 ET — Market closed Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors The modest gain came as Wall Street drifted lower in holiday-thinned trade. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, as investors repositioned after a tech-led run; the S&P 500 slipped 0.14% and the Nasdaq fell 0.23%. Reuters Why it matters now:
31 December 2025
··
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
··
GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a late-stage program can change a biotech’s outlook quickly because those trials sit closest to potential approvals and revenue. Genmab said on Monday it will discontinue further clinical development of acasunlimab after a portfolio review, citing a more competitive landscape. “After
30 December 2025
··
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

NEW YORK, December 30, 2025, 13:38 ET — Regular session Shares of Mineralys Therapeutics Inc fell 3.3% to $35.61 by early afternoon on Tuesday, after touching a session low of $35.17. About 513,000 shares had changed hands, versus a previous close of $36.83. Mineralys has a market value of about $2.9 billion and remains up about 183% over the past 52 weeks, even after sliding about 25% from its 52-week high set in November. Analysts expect the company to stay loss-making in the near term; Barchart shows an average quarterly EPS estimate of -$0.57 and an expected next earnings date
30 December 2025
··
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

NEW YORK, December 30, 2025, 13:14 ET — Regular session Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s close, with about 897,000 shares traded. The decline comes as investors focus on Corcept on the day the U.S. Food and Drug Administration is due to decide on relacorilant, its experimental treatment for endogenous hypercortisolism, also known as Cushing’s syndrome. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a target date for taking action on a
30 December 2025
··
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment. The stock swung between $318.08 and $275.00 during the day. The designation, known as BTD, is an FDA pathway meant to speed development and review of drugs for serious conditions when early clinical evidence suggests a meaningful improvement over available options. U.S. Food and Drug Administration Praxis said the BTD was granted for ulixacaltamide and that it expects to submit
30 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

NEW YORK, Dec. 28, 2025, 10:33 a.m. ET — Market Closed (Weekend) Eli Lilly and Company (NYSE: LLY) heads into the final two trading days of 2025 with U.S. markets closed for the weekend and investors weighing a familiar mix of catalysts: the booming obesity-drug franchise (Zepbound and Mounjaro), the intensifying race to bring weight-loss pills to market, and fast-evolving policy and pricing dynamics that could reshape demand. Reuters+2Reuters+2 LLY last closed at $1,077.75 on Friday (Dec. 26), with the session’s trading range roughly $1,068 to $1,081 on about 1.01 million shares, according to Investing.com’s historical data. That put the
28 December 2025
·
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 5:15 PM ET — Market closed. AbbVie Inc. (NYSE: ABBV) heads into the weekend with Wall Street shut and year-end positioning in full swing, after a quiet, post-holiday session on Friday left major U.S. indexes essentially unchanged. In thin trading, investors continue to weigh two competing narratives: a strong 2025 for equities and the seasonally bullish “Santa Claus rally” window — versus the reality that year-end liquidity can amplify moves on any surprise headline. Reuters Where AbbVie stock stands heading into Monday’s sessionAbbVie’s last trade/close sits at $229.98, leaving the stock near the upper end
27 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

NEW YORK, Dec. 27, 2025, 3:07 p.m. ET — Market closed Pfizer Inc. (NYSE: PFE) is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around the pharmaceutical giant as Wall Street debates two competing narratives: near-term pressure from fading COVID-era revenues and patent expirations, versus a longer-term rebuild driven by oncology and newer growth categories such as obesity. With U.S. equities closed for the weekend, investors won’t see fresh price discovery until Monday’s opening bell. That matters in a holiday-thinned tape—one where broad indexes have
27 December 2025
···
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 (10:08 a.m. ET) — Wave Life Sciences Ltd. (NASDAQ: WVE) is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF (XBI) is down about 1.07% and iShares Nasdaq Biotechnology ETF (IBB) is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green. That “WVE down while the market is up” headline can look ominous—until you zoom out and remember what happened earlier this month: Wave’s stock ripped higher on early obesity data, then the
26 December 2025
··
Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Eli Lilly (LLY) Stock After Hours Today (Dec. 25, 2025): Holiday Pause, GLP‑1 Catalysts, and What to Watch Before the Market Opens Dec. 26

Updated: Thursday, December 25, 2025 — U.S. exchanges are closed for Christmas Day, so the latest “after-hours” read for Eli Lilly and Company (NYSE: LLY) reflects trading following Wednesday’s holiday-shortened session. New York Stock Exchange Eli Lilly shares finished the most recent session at $1,076.98 after the early close on Dec. 24, then hovered just above that level in thin extended trading, with after-hours quotes clustering around $1,077–$1,078. StockAnalysis With the market reopening Friday, Dec. 26, investors are heading into the next trading day with a familiar setup for Lilly: strong momentum and premium valuation on one side, and a
25 December 2025
·
Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb (BMY) Stock News, Forecasts and Outlook as of Dec. 25, 2025: Breyanzi FDA Win, Eliquis Medicaid Deal, and 2026 Catalysts

Bristol-Myers Squibb Company (NYSE: BMY) heads into Dec. 25, 2025 with its stock anchored in the mid-$50s — and with investors juggling two competing storylines: With U.S. markets effectively pausing for the holiday, the most recent available NYSE quote showed BMY around $54.71 (last trade timestamp recorded Dec. 24), after trading between roughly $54.20 and $54.75 intraday. Bristol Myers Squibb Investors Bristol-Myers Squibb stock price today: where BMY stands into Dec. 25, 2025 BMS’s own investor quote page showed BMY at $54.71 on Dec. 24 (delayed quote), with a prior close listed as $54.28 and a 52-week range of $42.52
25 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb (BMY) Stock After Hours on Dec. 24, 2025: Key News, Forecasts, and What to Watch Before the Next Market Open

Bristol-Myers Squibb Company (NYSE: BMY) ended the Christmas Eve session with a modest gain—and then stayed largely quiet in after-hours trading as U.S. markets wrapped an early close and investors looked ahead to the next full session on Friday, Dec. 26 (U.S. markets are closed on Christmas Day, Dec. 25). New York Stock Exchange Even with the calm tape, today’s coverage of BMY wasn’t short on strong opinions: several market commentators leaned into the “value + dividend” case, while others argued the stock is now closer to fair value after a year-end rebound and policy headlines around Eliquis pricing. chartmill.com
25 December 2025
··
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see. As of 2:35 p.m. ET in after-hours trading on Wednesday, Dec. 24, 2025, OMER stock traded around $15.36, up about $6.59 (+75%) from the prior close, after swinging through a wide intraday range on heavy volume. This move matters not only because it’s dramatic — it’s because it’s tied to a hard catalyst: FDA approval of YARTEMLEA (narsoplimab‑wuug) for
24 December 2025
··
1 2 3 4 5 … 8

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Go toTop